Table 2 Efficacy of 240 mg of galcanezumab therapy at week 3 compared to baseline in patients with episodic cluster headache based on the headache diary (n = 33)
From: Real-world experience with 240 mg of galcanezumab for the preventive treatment of cluster headache
Baseline | Week 1 | Week 2 | Week 3 | Week 4 | Patients with a reduction of at least 50%, n (%) | Patients with a 100% reduction, n (%) | |
|---|---|---|---|---|---|---|---|
Number of attacks per week | 7.0 (6.0, 10.0) | 4.0 (1.0, 6.0) | 4.0 (0, 6.0) | 0 (0, 4.0) b | 0.0 (0, 1.0) | 26 (78.8) | 18 (54.5) |
Days with acute medications per weeka | 7.0 (3.0, 7.0) | 1.5 (0.0, 4.0) | 1 (0, 3.0) | 0 (0, 1.3) b | 0 (0, 0) | 23 (79.3) | 18 (62.1) |
Pain intensity during attacks [0–10] | 8.0 (7.0, 9.0) | 6.0 (4.8, 7.3) | 4.5 (0, 5.3) | 0 (0, 5.0) b | 0 (0, 1.8) | NA | NA |